JP2020502250A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502250A5 JP2020502250A5 JP2019534701A JP2019534701A JP2020502250A5 JP 2020502250 A5 JP2020502250 A5 JP 2020502250A5 JP 2019534701 A JP2019534701 A JP 2019534701A JP 2019534701 A JP2019534701 A JP 2019534701A JP 2020502250 A5 JP2020502250 A5 JP 2020502250A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxybutyrate
- ester
- glyceryltris
- administration
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical group CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 39
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 claims description 32
- -1 glyceryl (3-hydroxybutyrate) ester Chemical class 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 18
- 230000036470 plasma concentration Effects 0.000 claims description 18
- 208000019695 Migraine disease Diseases 0.000 claims description 16
- 206010027599 migraine Diseases 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 150000002576 ketones Chemical class 0.000 claims description 13
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 8
- CBTHKODKAPVTNY-UHFFFAOYSA-N 2,3-dihydroxypropyl 3-hydroxybutanoate Chemical compound CC(O)CC(=O)OCC(O)CO CBTHKODKAPVTNY-UHFFFAOYSA-N 0.000 claims 3
- 230000007062 hydrolysis Effects 0.000 claims 3
- 238000006460 hydrolysis reaction Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 claims 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical group CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 239000005862 Whey Substances 0.000 claims 1
- 102000007544 Whey Proteins Human genes 0.000 claims 1
- 108010046377 Whey Proteins Proteins 0.000 claims 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229940125961 compound 24 Drugs 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 description 3
- 230000037351 starvation Effects 0.000 description 3
- 230000036765 blood level Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000020887 ketogenic diet Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- AOWPVIWVMWUSBD-RNFRBKRXSA-N [(3r)-3-hydroxybutyl] (3r)-3-hydroxybutanoate Chemical compound C[C@@H](O)CCOC(=O)C[C@@H](C)O AOWPVIWVMWUSBD-RNFRBKRXSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035861 hyperketonemia Effects 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/389,828 | 2016-12-23 | ||
| US15/389,828 US20180177753A1 (en) | 2016-12-23 | 2016-12-23 | Glyceryl 3-hydroxybutyrates for migraine symptom management |
| PCT/US2017/063832 WO2018118369A1 (en) | 2016-12-23 | 2017-11-30 | Glyceryl 3-hydroxybutyrates for migraine symptom management |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502250A JP2020502250A (ja) | 2020-01-23 |
| JP2020502250A5 true JP2020502250A5 (enExample) | 2021-01-14 |
| JP7108320B2 JP7108320B2 (ja) | 2022-07-28 |
Family
ID=62624821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534701A Active JP7108320B2 (ja) | 2016-12-23 | 2017-11-30 | 片頭痛の症状を管理するためのグリセリル３－ヒドロキシブチラート |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180177753A1 (enExample) |
| EP (1) | EP3558458B1 (enExample) |
| JP (1) | JP7108320B2 (enExample) |
| KR (1) | KR102390608B1 (enExample) |
| CN (1) | CN110167637B (enExample) |
| BR (1) | BR112019012431A2 (enExample) |
| CA (1) | CA3046350C (enExample) |
| ES (1) | ES2962879T3 (enExample) |
| IL (1) | IL267540B (enExample) |
| MX (1) | MX389468B (enExample) |
| MY (1) | MY190308A (enExample) |
| PT (1) | PT3558458T (enExample) |
| WO (1) | WO2018118369A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12599579B2 (en) | 2016-04-19 | 2026-04-14 | Axcess Global Sciences, Llc | Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids |
| US12622889B2 (en) | 2016-04-19 | 2026-05-12 | Axcess Global Sciences, Llc | S-β-hydroxybutyrate esters for improving metabolic function |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US12533346B2 (en) | 2016-04-19 | 2026-01-27 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
| US12496283B2 (en) | 2016-04-19 | 2025-12-16 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| US12521378B2 (en) | 2016-04-19 | 2026-01-13 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans |
| US12329734B2 (en) | 2017-12-19 | 2025-06-17 | Axcess Global Sciences, Llc | Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow |
| US20230346721A1 (en) | 2018-04-18 | 2023-11-02 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies |
| CA3046415A1 (en) | 2016-12-21 | 2018-06-28 | Universitats-Kinderspital Beider Basel | Migraine prevention and treatment |
| US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
| GB201715654D0 (en) | 2017-09-27 | 2017-11-08 | Tdeltas Ltd | Method of treatment |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| CN113454055B (zh) * | 2019-01-17 | 2024-07-05 | 凯托利皮克斯治疗有限责任公司 | 生产包含基于羟基羧酸的甘油酯的结构单元的脂质的方法 |
| JP7235873B2 (ja) | 2019-01-17 | 2023-03-08 | アイオーアイ オレオ ゲーエムベーハー | ヒドロキシカルボン酸のグリセリドの製造方法 |
| EP3937656B1 (en) * | 2019-03-14 | 2025-04-02 | Neuroenergy Ventures, Inc. | Taste-masking formulation for ketone body compounds |
| US12472200B2 (en) | 2019-05-15 | 2025-11-18 | Axcess Global Sciences, Llc | Autobiotic compositions and method for promoting healthy gut microbiome |
| KR20220016145A (ko) | 2019-05-30 | 2022-02-08 | 뉴로에너지 벤처스 인코포레이티드 | 글리세릴 트리스(베타-하이드록시부티레이트) 및 신경 일과성 허혈 발작 |
| WO2020249198A1 (de) * | 2019-06-12 | 2020-12-17 | Ioi Oleo Gmbh | Verfahren zur herstellung von polyolbasierten estern von acylverkappten 3-hydroxycarbonsäuren |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US12167993B2 (en) | 2019-06-21 | 2024-12-17 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| IT201900018491A1 (it) * | 2019-10-10 | 2021-04-10 | Dr Schaer S P A | Procedimento di purificazione del tris-(3-idrossibutirrato)-gliceril estere |
| IT201900018488A1 (it) * | 2019-10-10 | 2021-04-10 | Dr Schaer S P A | Procedimento di preparazione del tris-(3-idrossibutirrato)-gliceril estere |
| US12186297B2 (en) | 2020-08-26 | 2025-01-07 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
| EP4405324A1 (en) | 2021-11-12 | 2024-07-31 | Arxada AG | Polyol-derived compounds |
| US20250002446A1 (en) * | 2021-11-26 | 2025-01-02 | Arxada Ag | Acetoacetate Based Ketals |
| US12622967B2 (en) * | 2022-01-18 | 2026-05-12 | Today, Inc. | Molecules, formulations, and methods for nutritional support of athletes, patients, and others |
| US12023382B2 (en) | 2022-01-18 | 2024-07-02 | Today Inc. | Molecules, formulations, and methods for nutritional support of athletes, patients, and others |
| EP4605371A1 (en) | 2022-10-18 | 2025-08-27 | Arxada AG | Polyol-derived compounds |
| WO2025074001A2 (en) | 2023-10-05 | 2025-04-10 | Arxada Ag | Enzymatic reduction of acetoacetate |
| WO2025196156A1 (en) | 2024-03-20 | 2025-09-25 | Arxada Ag | Continuous hydrogenation process of acetoacetate esters |
| WO2025224319A1 (en) | 2024-04-25 | 2025-10-30 | Arxada Ag | Reduction of acetoacetate esters in the presence of amines |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| PT2500017T (pt) | 2006-04-03 | 2017-11-14 | Accera Inc | Utilização de compostos cetogénicos para tratamento de comprometimento da memória associado à idade |
| US7807718B2 (en) * | 2006-06-30 | 2010-10-05 | Sami A. Hashim | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| CA2750510A1 (en) * | 2009-01-24 | 2010-07-29 | Phytopharm Plc | Treatment of neurotrophic factor mediated disorders |
| WO2012154837A2 (en) | 2011-05-09 | 2012-11-15 | University Of South Florida | The use of ketone esters for prevention of cns oxygen toxicity |
| US20140072654A1 (en) | 2011-12-23 | 2014-03-13 | Savind, Inc. | Cancer with metabolic therapy and hyperbaric oxygen |
| FR2997302B1 (fr) * | 2012-10-29 | 2015-02-06 | Assist Publ Hopitaux De Paris | Prevention et traitement des deficits en pyruvate deshydrogenase |
| JP6883384B2 (ja) | 2012-11-05 | 2021-06-09 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 電離放射線による傷害から組織を防護するためのケトン体 |
| EP2925308B1 (en) | 2012-11-28 | 2019-12-25 | University Of South Florida | Targeting cancer with metabolic therapy and hyperbaric oxygen |
| MY180761A (en) | 2013-03-19 | 2020-12-08 | Univ South Florida | Compositions and methods for producing elevated and sustained ketosis |
| GB201314127D0 (en) * | 2013-08-07 | 2013-09-18 | Tdeltas Ltd | Ketone body and ketone body ester for reducing muscle breakdown |
| WO2015156865A1 (en) | 2014-01-13 | 2015-10-15 | University Of South Florida | Methods of sustaining dietary ketosis and its effects on lipid profile |
| US20160078782A1 (en) * | 2014-09-17 | 2016-03-17 | The Trustees Of Boston College | Glucose Ketone Index for MetabolicTherapy |
| US9364456B1 (en) | 2015-06-30 | 2016-06-14 | University Of South Florida | Ketone esters for treatment of angelman syndrome |
| US20180200220A1 (en) | 2015-07-10 | 2018-07-19 | Cognate Nutritionals, Inc. | Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources |
| US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
| US10376482B2 (en) | 2016-04-03 | 2019-08-13 | Franco Cavaleri | Butyrate and beta-hydroxybutyrate compositions |
| SG11201809211QA (en) | 2016-04-19 | 2018-11-29 | Keto Patent Group Inc | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
| WO2018009208A1 (en) | 2016-07-08 | 2018-01-11 | Cognate Nutritionals, Inc. | Nutritional mitiggation of the cns effects of traumatic brain injury |
| JP2019526607A (ja) | 2016-09-12 | 2019-09-19 | ユニバーシティ・オブ・サウス・フロリダ | ケトンにより改善された神経再生 |
| CA3046415A1 (en) | 2016-12-21 | 2018-06-28 | Universitats-Kinderspital Beider Basel | Migraine prevention and treatment |
-
2016
- 2016-12-23 US US15/389,828 patent/US20180177753A1/en not_active Abandoned
-
2017
- 2017-11-30 IL IL267540A patent/IL267540B/en unknown
- 2017-11-30 CN CN201780078046.7A patent/CN110167637B/zh active Active
- 2017-11-30 BR BR112019012431A patent/BR112019012431A2/pt not_active Application Discontinuation
- 2017-11-30 PT PT178847570T patent/PT3558458T/pt unknown
- 2017-11-30 WO PCT/US2017/063832 patent/WO2018118369A1/en not_active Ceased
- 2017-11-30 KR KR1020197020923A patent/KR102390608B1/ko active Active
- 2017-11-30 ES ES17884757T patent/ES2962879T3/es active Active
- 2017-11-30 JP JP2019534701A patent/JP7108320B2/ja active Active
- 2017-11-30 CA CA3046350A patent/CA3046350C/en active Active
- 2017-11-30 EP EP17884757.0A patent/EP3558458B1/en active Active
- 2017-11-30 MY MYPI2019003609A patent/MY190308A/en unknown
- 2017-11-30 MX MX2019006844A patent/MX389468B/es unknown
-
2018
- 2018-12-14 US US16/220,365 patent/US10792269B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7108320B2 (ja) | 片頭痛の症状を管理するためのグリセリル３－ヒドロキシブチラート | |
| JP2020504134A5 (enExample) | ||
| JP2024015120A5 (enExample) | ||
| JP2018514534A5 (enExample) | ||
| KR20150130312A (ko) | 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법 | |
| JP2004517148A (ja) | 心機能不全および心不全の治療における必須ｎ−３脂肪酸 | |
| WO2010045787A1 (zh) | 人参皂苷化合物k在制备防治动脉粥样硬化的药物中的应用 | |
| JP2020510678A (ja) | 対象におけるマイトファジーを改善するための方法 | |
| CN101214049B (zh) | 一种具有辅助降血脂功能的保健食品 | |
| JP2020500864A5 (enExample) | ||
| US20190336523A1 (en) | Combination drug suitable for treatment and prevention of non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH), and/or hepatic fatty degeneration | |
| JP2016505050A5 (enExample) | ||
| CN109265419B (zh) | 硝基苯酯倍半萜类化合物在制备抗炎药物中的应用 | |
| JP7314391B2 (ja) | リゾチームを含む医薬組成物およびその使用 | |
| JP2024526939A5 (enExample) | ||
| CN109999044B (zh) | 一种含有醉茄素a的组合物及其应用 | |
| CN109908165B (zh) | 一种含有雷公藤红素的组合物及其应用 | |
| CN101485679B (zh) | 一种预防和治疗高血脂的药物 | |
| US11058718B2 (en) | Method for treating non-alcoholic steatohepatitis (NASH) with the combination of polaprezinc and sodium selenite | |
| CN112386696A (zh) | 一种治疗胰岛素抵抗的靶点及其应用 | |
| US12521413B2 (en) | Molecular basis of fatty liver inhibition by sodium borates | |
| CN107281184A (zh) | 一种调控脂代谢的方法及其药物 | |
| JPS5938206B2 (ja) | 補酵素ｑを主成分とする気管支喘息治療剤 | |
| Kumar et al. | Comparative Clinical Evaluation of Yogic Practices and Apamarga Tandula (Seeds) along with their Additive Effect in Sthaulya (Obesity) | |
| JP2024542844A5 (enExample) |